Having trouble accessing articles? Reset your cache.

Spreading Carma

Carma Therapeutics uses CAR macrophages to eat up solid tumors

Carma Therapeutics LLC is subverting macrophages’ tumor-promoting role by engineering in chimeric antigen receptors (CARs) to turn the phagocytic cells into agents that suppress the growth of solid tumors.

The company is a translational play from the lab of Saar Gill, and has spun out from the University of Pennsylvania with a soon-to-be-announced seed funding. Carma hopes to raise up

Read the full 605 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers